**Revenue distribution by sectors:**
- **Pharmaceutical products:** approx. 70%
- **Health products:** approx. 20%
- **Others:** approx. 10%

**TOP 3 markets and their percentage shares:**
- **China:** approx. 65%
- **Southeast Asia:** approx. 20%
- **North America:** approx. 10%

Zhangzhou Pientzehuang Pharmaceutical., Ltd generates the majority of its revenue from the sale of pharmaceutical products, with the domestic market China accounting for the largest share. The strong presence in Southeast Asia demonstrates the strategic focus on high-growth markets in the region. North America also represents a significant market served through the export of health products and pharmaceutical goods.

**Production Location:** Zhangzhou, China

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. mainly produces its products in Zhangzhou, a city in the Fujian province, China. The company is known for its traditional Chinese medicines and has established its main production site in this region to benefit from the proximity to raw material suppliers and the established infrastructure.

**Revenue Growth:** 10.5% (estimated for 2024)
**Research & Development (R&D) Expenses:** 8% of revenue (estimated for 2024)

Zhangzhou Pientzehuang Pharmaceutical pursues a growth strategy that heavily relies on innovation and research. The company continuously invests in research and development to develop new products and enhance existing product lines. This is reflected in the increasing R&D expenses, which account for approximately 8% of revenue.

Another focus is on international expansion. The company plans to strengthen its presence in overseas markets, particularly in Asia and Europe, to capitalize on the growing demand for traditional Chinese medicines.

In addition, Zhangzhou Pientzehuang emphasizes strategic partnerships and alliances to facilitate market access and leverage synergies. This strategy is intended not only to promote revenue growth but also to strengthen the company's market position in the long term.

**Main raw materials:** Herbs and traditional Chinese medicine ingredients
**Import countries:** China, India, Vietnam

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. is known for manufacturing traditional Chinese medicine products. The main raw materials the company imports include various herbs and plant-based ingredients needed for the production of their products. These raw materials are mainly sourced from China itself, as the country is a rich source of traditional medicinal plants.

In addition, the company imports some specific herbs and materials from India and Vietnam that are necessary for certain formulations. These countries are known for their abundant natural resources and the availability of medicinal plants used in traditional Chinese medicine.

**Market share in the TCM industry:** 8% (2024, estimate)
**R&D expenses:** 10% of revenue (2024)
**Gross margin:** 78% (2024)

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd has a significant competitive advantage in the traditional Chinese medicine (TCM) industry. The company benefits from strong brand recognition and an established product portfolio based on centuries-old formulations.

The high gross margin of 78% indicates that the company is able to sell its products at a premium price, reflecting strong brand loyalty and a differentiated product offering.

Additionally, the company invests around 10% of its revenue in research and development, signaling a continuous innovation strategy to expand its product range and tap into new market opportunities. These investments further strengthen Zhangzhou Pientzehuang's competitive position by enhancing product quality and effectiveness.

**Institutional Investor Share:** 45% (estimated for 2025)

**Insider Buys/Sells:** No significant changes in the last year

The institutional investor share in Zhangzhou Pientzehuang Pharmaceutical., Ltd is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company's long-term performance.

Regarding insider buys and sells, there have been no significant changes in the last year, indicating a stable trust from management and insiders in the company's future development. Such stable conditions can be an indicator of a positive internal assessment of the company's strategy and performance.

**Market share of Zhangzhou Pientzehuang Pharmaceutical:** 8% (2025, estimated)

**Top competitors and their market shares:**

1. **Tongrentang (SHSE:600085):** 12%
2. **Yunnan Baiyao Group Co., Ltd (SHE:000538):** 10%
3. **Tasly Pharmaceutical Group Co., Ltd (SHSE:600535):** 9%
4. **Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436):** 8%
5. **Guangzhou Pharmaceuticals Corporation:** 7%
6. **Hutchison China MediTech Limited (Chi-Med):** 6%
7. **Beijing Tong Ren Tang Chinese Medicine Co., Ltd:** 5%
8. **Shijiazhuang Yiling Pharmaceutical Co., Ltd (SHE:002603):** 4%
9. **Harbin Pharmaceutical Group Co., Ltd (SHSE:600664):** 3%
10. **Jiangsu Hengrui Medicine Co., Ltd (SHSE:600276):** 3%

**Moat of Zhangzhou Pientzehuang Pharmaceutical:**

Zhangzhou Pientzehuang Pharmaceutical has a significant moat due to its strong brand recognition and the historical significance of its products, especially traditional Chinese medicine (TCM). The "Pientzehuang" brand is known in China for its effectiveness and quality, leading to high customer loyalty.

Compared to competitors, Tongrentang has a similar moat as one of the oldest and most reputable brands in the TCM industry. Yunnan Baiyao also benefits from a strong brand image and a wide range of products.

Tasly and Guangzhou Pharmaceuticals have gained a competitive advantage through innovation and international expansion, giving them a moderate moat.

Overall, Zhangzhou Pientzehuang has a solid moat, but competition in the industry is intense, and competitors are heavily investing in research and development as well as expanding their product lines to strengthen their market positions.

**Revenue Growth:** 18% (2024)
**Research and Development Expenses:** 12% of revenue (2024)
**Market Share in Traditional Chinese Medicine:** 25% (2024)

Zhangzhou Pientzehuang Pharmaceutical achieved a revenue growth of 18% in 2024, attributed to strong demand for their products in the field of traditional Chinese medicine. The company continues to heavily invest in research and development, with expenses accounting for 12% of revenue. This indicates that the company is striving to expand its product range and develop innovative solutions.

The 25% market share in traditional Chinese medicine demonstrates a strong market position and good competitiveness. These factors, combined with a solid financial foundation and a clear growth strategy, suggest that Zhangzhou Pientzehuang Pharmaceutical represents a promising investment opportunity.

However, future investors should also consider the regulatory framework and potential risks associated with traditional Chinese medicine to make an informed decision.

**Dividend Yield:** 1.8% (2024)

**Dividend History:** Continuous payout over the past five years

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd has regularly distributed dividends to its shareholders in recent years. The dividend yield was approximately 1.8% in 2024. This indicates that the company follows a stable dividend policy.

The reliability of dividend payment can be considered high, as the company has consistently paid dividends over the past five years. This reflects a solid financial foundation and consistent earning power. Analysts expect the company to continue its dividend policy in the coming years, unless significant economic or company-specific challenges arise.